ArticleJournal of applied clinical medical physics2023
Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans.
Article in Journal of applied clinical medical physics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- AAPM-RSS Medical Physics Practice Guideline 9.b: SRS-SBRT.Journal of applied clinical medical physics · 2025Guideline
- Site-specific performance and complexity-dependent risk assessment of patient-specific quality assurance using a 2D array detector in CyberKnife radiosurgery.Radiological physics and technology · 2026Article
- Predicting VMAT patient-specific quality assurance outcome using a machine learning workflow.Physical and engineering sciences in medicine · 2026Article
- Evaluation of EPID-Based Transmission and DLG Correction Methods for Dosimetric Verification in HyperArc Single-Isocenter Multiple Target Radiosurgery.Diagnostics (Basel, Switzerland) · 2026Article
- Impact of field number and monitor units per segment on magnetic resonance-guided hypofractionated stereotactic radiotherapy for brain metastases: plan quality, deliverability, and robustness trade-offs.Quantitative imaging in medicine and surgery · 2026Article
- Multi-institutional study of multileaf collimator parameters and dose calculation accuracy using the enhanced leaf model.Radiological physics and technology · 2026Article
- A component-wise commissioning and validation framework for non-transit electronic portal imaging device patient-specific quality assurance.Physics and imaging in radiation oncology · 2026Article
- Assessment of rotational dose perturbations in SBRT: A radiomic-dosiomic predictive model based on the structural similarity index measure.Journal of applied clinical medical physics · 2026Article
- Efficacy and clinical use of novel high-resolution EPID-based 2D and 3D automated patient-specific quality assurance for SRS and SBRT patients.Radiation and environmental biophysics · 2026Article
- Patient-specific quality assurance for extremely small field sizes using 3D in vivo dosimetry in fractionated stereotactic radiosurgery for brain metastases.Journal of applied clinical medical physics · 2026Article
- Article
- Feasibility study of a multi-lesion cyberknife radiotherapy plan verification method using a 2D array with pre-set roll angles.Precision radiation oncology · 2025Article
- A Beam Orientation Quality Assurance Framework for Gyroscopic Stereotactic Radiosurgery Systems.Cureus · 2025Article
- Dosimetric commissioning of a high-resolution CMOS 2D detector array for patient-specific QA of single-isocenter multi-target VMAT stereotactic radiosurgery.Journal of radiation research · 2024Article
- Dosimetric effects of small field size, dose grid size, and variable split-arc methods on gamma pass rates in radiation therapy.Radiological physics and technology · 2024Article
- Assessing the sensitivity and suitability of a range of detectors for SIMT PSQA.Journal of applied clinical medical physics · 2024Article
- Commissioning and clinical evaluation of a novel high-resolution quality assurance digital detector array for SRS and SBRT.Journal of applied clinical medical physics · 2024Article
- Dosimetric Systems in Pre-Treatment QA for Stereotactic Treatments: Correlation Agreements and Target Volume Dependency.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Systematic evaluation of spatial resolution and gamma criteria for quality assurance with detector arrays in stereotactic radiosurgery.Journal of applied clinical medical physics · 2024Article
- Evaluation of commercial devices for patient specific QA of stereotactic radiotherapy plans.Journal of applied clinical medical physics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic radiotherapy (SRT) methods have become common for the treatment of small tumors in various parts of the body. Small field dosimetry has a unique set of challenges when it comes to the pre-treatment validation of a radiotherapy plan that involves film dosimetry or high-resolution detectors. Comparison of commercial quality assurance (QA) devices to the film dosimetry method for pre-treatment evaluation of stereotactic radiosurgery (SRS), fractionated SRT, and stereotactic body radiation therapy treatment plans have been evaluated in this study. Forty stereotactic QA plans were measured using EBT-XD film, IBA Matrixx Resolution, SNC ArcCHECK, Varian aS1200 EPID, SNC SRS MapCHECK, and IBA myQA SRS. The results of the commercial devices are compared to the EBT-XD film dosimetry results for each gamma criteria. Treatment plan characteristics such as modulation factor and target volume were investigated for correlation with the passing rates. It was found that all detectors have greater than 95% passing rates at 3%/3 mm. Passing rates decrease rapidly for ArcCHECK and the Matrixx as criteria became more strict. In contrast, EBT-XD film, SNC SRS MapCHECK, and IBA myQA SRS passing rates do not decline as rapidly when compared to Matrix Resolution, ArcCHECK, and the EPID. EBT-XD film, SNC SRS MapCHECK, and IBA myQA SRS maintain greater than 90% passing rate at 2%/1 mm and greater than 80% at 1%/1 mm. Additionally, the ability of these devices to detect changes in dose distribution due to MLC positioning errors was investigated. Ten VMAT SBRT/SRS treatment plans were created with 6 MV FFF or 10 MV FFF beam energies using Eclipse 15.6. A MATLAB script was used to create two MLC positioning error scenarios from the original treatment plan. It was found that errors in MLC positioning were most reliably detected at 2%/1 mm for high-resolution detectors and that lower-resolution detectors did not consistently detect MLC positioning errors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.